Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta1.00
Shares Outstanding14.6M
Average Volume (10 days)90.1K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.76)
Sales (TTM)$10.39
Book Value (MRQ)$19.60
Cash Flow (TTM)$0.53
Cash (MRQ)$6.28

Analyst Views

Current Mean RecommendationHold
Strong Buy0
 
Buy0
 
Hold2
 
Underperform0
 
Sell0
 

Recent Insider Transactions

John B. Henneman
Director
7,954
Acquire
Jun 8, 2022
Sheryl L. Conley
Director
7,954
Acquire
Jun 8, 2022
Susan L.N. Vogt
Director
7,954
Acquire
Jun 8, 2022
Stephen Richard
Director
7,954
Acquire
Jun 8, 2022
Glenn R. Larsen
Director
7,954
Acquire
Jun 8, 2022

Recent SEC Filings

4
Insider Buy/Sell
Aug 11, 2022
S-8
S-8
Aug 5, 2022
10-Q
Quarterly Financials
Aug 4, 2022
8-K
Company Events
Aug 3, 2022
4
Insider Buy/Sell
Jun 10, 2022
Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.
To Top